Adenoscan is a drug owned by Astellas Pharma Us Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 24, 2015. Details of Adenoscan's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5731296 | Selective vasodilation by continuous adenosine infusion |
Mar, 2015
(9 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Adenoscan is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Adenoscan's family patents as well as insights into ongoing legal events on those patents.
Adenoscan's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Adenoscan's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 24, 2015 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Adenoscan Generic API suppliers:
Adenosine is the generic name for the brand Adenoscan. 14 different companies have already filed for the generic of Adenoscan, with Fresenius Kabi Usa having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Adenoscan's generic
How can I launch a generic of Adenoscan before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Adenoscan's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Adenoscan's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Adenoscan -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 3 mg/mL, 20 mL and 30 mL vials | 18 Apr, 2005 | 1 | 29 Aug, 2013 | 24 Mar, 2015 | Eligible |
About Adenoscan
Adenoscan is a drug owned by Astellas Pharma Us Inc. It is used for improving blood flow in certain areas of the body. Adenoscan uses Adenosine as an active ingredient. Adenoscan was launched by Astellas in 1995.
Approval Date:
Adenoscan was approved by FDA for market use on 18 May, 1995.
Active Ingredient:
Adenoscan uses Adenosine as the active ingredient. Check out other Drugs and Companies using Adenosine ingredient
Treatment:
Adenoscan is used for improving blood flow in certain areas of the body.
Dosage:
Adenoscan is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 90MG/30ML (3MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION | Discontinued | INTRAVENOUS |
| 60MG/20ML (3MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION | Discontinued | INTRAVENOUS |